JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Recruiting now · Phase 2

Conditions studied: B-cell Non-Hodgkin's Lymphoma

In brief

To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma

Key facts

Study ID

NCT07081022

Run by

Shanghai Junshi Bioscience Co., Ltd.

People needed

180

Starts

2025-08-17

Expected to finish

2027-04-06

Last updated by the study team

2025-08-21

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must meet all of the following inclusion criteria to be enrolled：
• Age range: 18 to 80 years old (inclusive), both male and female are acceptable；
• ECOG: 0-2；
• B-cell non-Hodgkin's lymphoma expressing CD20 antigen that has been pathologically diagnosed；
• At least one measurable lesion meeting the criteria specified in the Lugano 2014 response assessment； Acceptable organ function at screening；

You may not qualify if…

• A history of severe allergy to monoclonal antibody therapy (or recombinant antibody-related fusion protein)；
• Previously received CD20-CD3 bispecific antibody treatment；
• Previous allogeneic hematopoietic stem cell transplantation；
• Previous solid organ transplantation；
• History of autoimmune diseases；
• Patients with a history of macrophage activation syndrome (MAS)/ hemophagocytic lymphohistiocytosis (HLH)；
• Patients with a history of progressive multifocal leukoencephalopathy (PML)；
• A known or suspected history of CNS lymphoma (including primary or secondary)；
• There is pleural effusion, peritoneal effusion or pericardial effusion that requires treatment (such as puncture or drainage)；

Where it is running

• Beijing Cancer Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.